FDA extended the aficamten decision deadline to Dec. 26 after classifying the REMS submission as a major amendment to the NDA review.
FDA Pushes Potential Approval For Cytokinetics’ Experimental Heart Drug By Three Months
Where Today's News Shapes Tomorrow
